Quick Answer
Citius Pharmaceuticals, Inc. reported Net Income Loss of -$32.54 million for the year ending 2023.
- Citius Pharmaceuticals, Inc. showed an increase of +3.3% in Net Income Loss from 2022 to 2023.
- This data is from Citius Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on December 29, 2023.
- XBRL data for this metric is available from 2010 to 2023 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2013: -$4.4 thousand | Q4 2013: -$534.4 thousand | Q1 2014: -$90.3 thousand | Q2 2014: -$34.9 thousand | Q4 2014: -$823.7 thousand | Q1 2015: -$345.3 thousand | Q2 2015: -$825.0 thousand | Q4 2015: -$1.22 million | Q1 2016: -$869.5 thousand | Q2 2016: -$3.62 million | Q4 2016: -$2.18 million | Q1 2017: -$2.74 million | Q2 2017: -$2.42 million | Q4 2017: -$3.25 million | Q1 2018: -$4.42 million | Q2 2018: -$2.02 million | Q4 2018: -$3.87 million | Q1 2019: -$3.63 million | Q2 2019: -$4.41 million | Q4 2019: -$4.32 million | Q1 2020: -$4.42 million | Q2 2020: -$4.68 million | Q4 2020: -$8.15 million | Q1 2021: -$4.12 million | Q2 2021: -$5.82 million | Q4 2021: -$9.23 million | Q1 2022: -$7.56 million | Q2 2022: -$8.86 million | Q4 2022: -$3.59 million | Q1 2023: -$10.53 million | Q2 2023: -$8.48 million | Q4 2023: $9.23 million | Q1 2024: -$8.54 million | Q2 2024: -$10.57 million | Q4 2024: -$10.28 million | Q1 2025: -$11.51 million.
- Over the full 16 years of available data (2010 to 2023), Citius Pharmaceuticals, Inc.'s Net Income Loss has declined by 209,854.3%.
- Historical annual values: Fiscal year 2023: -$32.54 million | Fiscal year 2022: -$33.64 million | Fiscal year 2021: -$23.05 million | Fiscal year 2020: -$17.55 million | Fiscal year 2019: -$15.56 million | Fiscal year 2018: -$12.54 million | Fiscal year 2017: -$10.38 million | Fiscal year 2016: -$8.30 million | Fiscal year 2015: -$2.90 million | Fiscal year 2014: -$737.7 thousand | Fiscal year 2013: -$1.29 million | Fiscal year 2013: -$31.4 thousand | Fiscal year 2012: -$22.0 thousand | Fiscal year 2011: -$26.3 thousand | Fiscal year 2010: -$15.5 thousand | Fiscal year 2010: -$15.5 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: